Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic kidney disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    745 result(s) found for: Chronic kidney disease. Displaying page 1 of 38.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022994-32 Sponsor Protocol Number: 34009 Start Date*: 2011-06-24
    Sponsor Name:UMC Utrecht
    Full Title: Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease
    Medical condition: Chronic kidney disease End stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064848 Chronic kidney disease LLT
    12.1 10014646 End stage renal disease (ESRD) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002551-11 Sponsor Protocol Number: HP-CKDPKD Start Date*: 2022-01-18
    Sponsor Name:Aarhus University
    Full Title: Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI
    Medical condition: Chronic kidney disease and polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018838-45 Sponsor Protocol Number: RLY5016–204 Start Date*: 2010-04-21
    Sponsor Name:Relypsa, Inc.
    Full Title: A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for RLY5016 in Heart Failure Patients with Chronic Kidney Disease
    Medical condition: Heart failure with Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008908 Chronic heart failure LLT
    12.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-000995-13 Sponsor Protocol Number: DECODE-CKD Start Date*: 2022-01-26
    Sponsor Name:Department of Cardiology, Herlev and Gentofte hospital
    Full Title: A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004099-26 Sponsor Protocol Number: 6.version,september2011 Start Date*: 2009-12-10
    Sponsor Name:Departmnet of nephrology
    Full Title: Randomised trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function.
    Medical condition: decreased renal function (CKD II-IV), creatinin clearance 15-90 ml/min
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    18.0 10038359 - Renal and urinary disorders 10013231 Disorder kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000740-29 Sponsor Protocol Number: 270389-030122 Start Date*: 2022-04-12
    Sponsor Name:Department of Renal Medicine, Aarhus University Hospital
    Full Title: Sodium glucose cotransporter 2 inhibitors or Mineralocorticoid receptor antagonists for the treatment of Albuminuric Chronic Kidney Disease - A randomized controlled trial
    Medical condition: Chronic Kidney Disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000421-27 Sponsor Protocol Number: 21177 Start Date*: 2022-01-07
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression o...
    Medical condition: Non-diabetic chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) CZ (Trial now transitioned) ES (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002267-25 Sponsor Protocol Number: PIVOTAL Start Date*: 2013-09-06
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients
    Medical condition: Iron-deficiency in anaemia of end stage renal disease.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10064848 Chronic kidney disease LLT
    16.0 100000004851 10066763 Chronic iron deficiency anaemia LLT
    16.0 100000004865 10066623 Chronic haemodialysis LLT
    16.0 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000431-40 Sponsor Protocol Number: UF9672 Start Date*: 2016-05-19
    Sponsor Name:Health Ministry
    Full Title: Randomized controlled study evaluating the effect of a biotherapy treatment (anti-RANKL ligand antibody: Denosumab) on bone and vascular metabolism in osteoporotic chronic kidney disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10009119 Chronic renal failure LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003727-23 Sponsor Protocol Number: RRK3563 Start Date*: 2008-12-16
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: Does phosphate binding with sevelamer carbonate improve cardiovascular structure and function in patients with early chronic kidney disease?
    Medical condition: Chronic kidney disease stage 3 (eGFR 30-59 ml/min/1.73m2)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002192-35 Sponsor Protocol Number: 19225 Start Date*: 2020-10-13
    Sponsor Name:Bayer - AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²)...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000410-37 Sponsor Protocol Number: 310107 Start Date*: 2007-09-26
    Sponsor Name:University Of Tuebingen
    Full Title: Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016531-35 Sponsor Protocol Number: SPD405-703 Start Date*: 2010-05-18
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Sta...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005003-88 Sponsor Protocol Number: SIM15 Start Date*: 2016-03-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Survival Improvement with Cholecalciferol in Patients on Dialysis – The SIMPLIFIED Registry Trial
    Medical condition: Kidney Failure (requiring dialysis).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000070575 10023420 Kidney failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002586-38 Sponsor Protocol Number: RPH-1101 Start Date*: 2011-10-14
    Sponsor Name:Renapharma AB
    Full Title: A 12-week clinical double-blind, randomised study of cholecalciferol versus placebo in patients with chronic kidney disease stage 3-4 (CHICK).
    Medical condition: Chronic renal failure, stage 3-4
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10038444 Renal failure chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002893-20 Sponsor Protocol Number: 2021/0188/HP Start Date*: 2021-12-03
    Sponsor Name:CHU de Rouen
    Full Title: Impact of dapagliflozin on vascular function in chronic kidney disease patients
    Medical condition: chronic kidney disease patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012445-35 Sponsor Protocol Number: ALBLOCK-2 Start Date*: 2009-11-26
    Sponsor Name:Herlev Hospital
    Full Title: Aldosterone receptor blockade in patients with chronic kidney disease. Influence on arterial stiffness and kidney function.
    Medical condition: Chronic kidney disease, stages 3 and 4.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001033-12 Sponsor Protocol Number: 12020 Start Date*: 2020-10-13
    Sponsor Name:Niels Eske Bruun
    Full Title: PROPHYLACTIC ANTIBIOTIC TREATMENT IN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER AS HEMODIALYSIS VASCULAR ACCESS
    Medical condition: Severe infection in patients end stage kidney disease and in hemodialysis with CVC as vascular asscess.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10023420 Kidney failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001296-32 Sponsor Protocol Number: FC/HULP-2014_01 Start Date*: 2014-07-07
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz
    Full Title: Pharmacokinetic and pharmacodynamic optimization of amikacin treatment in patients with terminal renal failure under conventional hemodialysis: randomized clinical trial of two model of administration
    Medical condition: Terminal renal failure under hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10038444 Renal failure chronic PT
    17.0 10038359 - Renal and urinary disorders 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002930-33 Sponsor Protocol Number: 1366-0022 Start Date*: 2021-09-02
    Sponsor Name:Boehringer Ingelheim Pharma GmbH&Co.
    Full Title: Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in p...
    Medical condition: non-diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) PT (Completed) DE (Completed) PL (Completed) ES (Restarted)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:28:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA